Table 1 Demographic and clinical variables of the 26 study patients
From: IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
Patients(N) | Age (average ± SD) (rank) | Gender (M/F,%) (N) | Age at onset (average ± SD) (rank) | Disease duration (years) (average ± SD) (rank) | Expanded CAG repeats (average ± SD) (rank) | Baseline SARA (average ± SD) (rank) |
|---|---|---|---|---|---|---|
SCA3 (19) | 50.32 ± 13.60 (28 – 74) | 68.4/31.6 (13/6) | 40.53 ± 12.19 (20 – 62) | 9.84 ± 7.41 (2 – 30) | 47.3 ± 33.5 (52 – 75) | 11.89 ± 4.82 (8 – 28) |
SCA7 (6) | 45.71 ± 16.86 (28 – 66) | 71.4/28.6 (5/2) | 34.71 ± 10.87 (23 – 48) | 11.00 ± 6.02 (4 – 18) | 43.3 ± 24.3 (34 – 50) | 16.19 ± 6.32 (8–27) |
SCA6 (1) | 55 | 100/0 | 48 | 7 | 23 | 14 |
Total (26) | 49.30 ± 14.12 (28–74) | 70.37/29.63 (19/8) | 39.3 ± 11.83 (20 – 62) | 10.04 ± 6.92 (2 – 30) | ─ | 13.17 ± 5.38 (8 – 28) |